Phase 3 Study Comparing Daratumumab, Lenalidomide, and Dexamethasone (DRd) vs Lenalidomide and Dexamethasone (Rd) in Subjects With Relapsed or Refractory Multiple Myeloma

Trial Profile

Phase 3 Study Comparing Daratumumab, Lenalidomide, and Dexamethasone (DRd) vs Lenalidomide and Dexamethasone (Rd) in Subjects With Relapsed or Refractory Multiple Myeloma

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 27 Sep 2017

At a glance

  • Drugs Daratumumab (Primary) ; Dexamethasone; Lenalidomide
  • Indications Multiple myeloma
  • Focus Registrational; Therapeutic Use
  • Acronyms POLLUX
  • Sponsors Janssen Research & Development
  • Most Recent Events

    • 27 Sep 2017 According to a Genmab media release, the Ministry of Health, Labor and Welfare in Japan has approved daratumumab in combination with lenalidomide and dexamethasone or bortezomib and dexamethasone for the treatment of adults with relapsed and refractory multiple myeloma. The approval is based on data from this and CASTOR trial.
    • 12 Sep 2017 Results evaluating the management of daratumumab related infusion-related reactions (IRRs) in the phase 3 studies CASTOR and POLLUX presented at the 42nd European Society for Medical Oncology Congress
    • 25 Jun 2017 Results assessing the efficacy Daratumumab in combination with lenalidomide and dexamethasone or bortezomib and dexamethasone in relapsed or refractory multiple myeloma patients with standard or high cytogenetic risk status from CASTOR and POLLUX studies, presented at the 22nd Congress of the European Haematology Association.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top